Solventum (NYSE:SOLV) Upgraded to “Hold” at BMO Capital Markets

BMO Capital Markets upgraded shares of Solventum (NYSE:SOLV) to a hold rating in a research note published on Wednesday morning,Zacks.com reports.

SOLV has been the subject of a number of other reports. Wedbush began coverage on shares of Solventum in a research note on Friday, May 15th. They set an “outperform” rating and a $94.00 target price for the company. Piper Sandler dropped their price target on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Wells Fargo & Company cut their price target on Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a report on Wednesday, May 6th. BTIG Research reiterated a “buy” rating and set a $89.00 price objective on shares of Solventum in a research report on Wednesday, May 6th. Finally, Weiss Ratings lowered Solventum from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, June 26th. Seven research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $83.50.

Solventum Price Performance

Shares of NYSE SOLV opened at $76.02 on Wednesday. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.07 and a quick ratio of 0.75. The firm has a market capitalization of $13.17 billion, a PE ratio of 9.32, a P/E/G ratio of 1.16 and a beta of 0.66. Solventum has a 1-year low of $62.38 and a 1-year high of $88.20. The business’s fifty day moving average price is $76.04 and its two-hundred day moving average price is $74.30.

Solventum (NYSE:SOLV) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.35 by $0.13. The company had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The company’s revenue for the quarter was down 3.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.34 earnings per share. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, research analysts expect that Solventum will post 6.58 EPS for the current year.

Institutional Investors Weigh In On Solventum

A number of institutional investors have recently added to or reduced their stakes in SOLV. Assetmark Inc. increased its position in shares of Solventum by 21.4% during the 4th quarter. Assetmark Inc. now owns 725 shares of the company’s stock valued at $57,000 after purchasing an additional 128 shares during the period. Hilltop National Bank lifted its holdings in shares of Solventum by 71.3% in the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after buying an additional 129 shares during the period. Allworth Financial LP boosted its stake in Solventum by 2.8% during the third quarter. Allworth Financial LP now owns 4,788 shares of the company’s stock valued at $350,000 after buying an additional 129 shares in the last quarter. CIBC Private Wealth Group LLC boosted its stake in Solventum by 0.5% during the third quarter. CIBC Private Wealth Group LLC now owns 24,710 shares of the company’s stock valued at $1,804,000 after buying an additional 134 shares in the last quarter. Finally, BOKF NA grew its holdings in Solventum by 6.9% during the third quarter. BOKF NA now owns 2,193 shares of the company’s stock worth $160,000 after acquiring an additional 141 shares during the period.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.